John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$510M |
| 2 |
Broadcom
AVGO
|
+$318M |
| 3 |
Marvell Technology
MRVL
|
+$290M |
| 4 |
Salesforce
CRM
|
+$263M |
| 5 |
Advanced Micro Devices
AMD
|
+$250M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$255M |
| 2 |
Progressive
PGR
|
+$244M |
| 3 |
Visa
V
|
+$238M |
| 4 |
Lam Research
LRCX
|
+$201M |
| 5 |
Elevance Health
ELV
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.88% |
| 2 | Healthcare | 13.28% |
| 3 | Financials | 10.32% |
| 4 | Industrials | 9.79% |
| 5 | Consumer Discretionary | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
inTEST
INTT
$145M
| $136K | ﹤0.01% |
19,398
-25,824
| -57% | -$214K |
|
2852
ARS Pharmaceuticals
SPRY
$532M
| $135K | ﹤0.01% |
10,771
-87,307
| -89% | -$1.05M |
|
2853
Celcuity
CELC
$4.44B
| $135K | ﹤0.01% |
13,378
-38,460
| -74% | -$435K |
|
|
UPB
2854
Upstream Bio Inc
UPB
$362M
| $133K | ﹤0.01% |
+21,789
| New | +$208K |
|
2855
eGain
EGAN
$196M
| $133K | ﹤0.01% |
27,426
-33,106
| -55% | -$187K |
|
|
HLVX
2856
DELISTED
HilleVax
HLVX
| $132K | ﹤0.01% |
90,715
+35,180
| +63% | +$65K |
|
|
PONY
2857
Pony AI Inc
PONY
$3.28B
| $131K | ﹤0.01% |
+14,885
| New | +$212K |
|
2858
CI&T Inc
CINT
$474M
| $131K | ﹤0.01% |
21,973
+3,733
| +20% | +$25.1K |
|
2859
Microvast
MVST
$298M
| $130K | ﹤0.01% |
111,476
+35,328
| +46% | +$61.4K |
|
2860
Epsilon Energy
EPSN
$170M
| $129K | ﹤0.01% |
18,269
-7,556
| -29% | -$49.4K |
|
2861
Myriad Genetics
MYGN
$292M
| $129K | ﹤0.01% |
+14,500
| New | +$174K |
|
2862
Hycroft Mining Holding Corp
HYMC
$2.4B
| $129K | ﹤0.01% |
39,665
+27,259
| +220% | +$70K |
|
|
ONL
2863
Orion Office REIT
ONL
$166M
| $128K | ﹤0.01% |
60,028
-97,197
| -62% | -$339K |
|
|
ARI
2864
Apollo Commercial Real Estate
ARI
$883M
| $127K | ﹤0.01% |
+13,313
| New | +$126K |
|
2865
Lexeo Therapeutics
LXEO
$404M
| $127K | ﹤0.01% |
+36,624
| New | +$162K |
|
2866
Neurogene
NGNE
$793M
| $127K | ﹤0.01% |
10,844
-9,785
| -47% | -$170K |
|
2867
TScan Therapeutics
TCRX
$54.2M
| $124K | ﹤0.01% |
+90,201
| New | +$195K |
|
|
FBLA
2868
FB Bancorp
FBLA
$230M
| $123K | ﹤0.01% |
+10,961
| New | +$125K |
|
2869
Rezolute
RZLT
$482M
| $123K | ﹤0.01% |
42,531
-16,932
| -28% | -$73.7K |
|
|
SIFY
2870
Sify Technologies
SIFY
$1.03B
| $123K | ﹤0.01% |
28,736
+5,960
| +26% | +$23.8K |
|
2871
Mission Produce
AVO
$1.16B
| $123K | ﹤0.01% |
11,715
-52,402
| -82% | -$611K |
|
|
SION
2872
Sionna Therapeutics
SION
$253M
| $123K | ﹤0.01% |
+11,715
| New | +$191K |
|
|
LAND
2873
Gladstone Land Corp
LAND
$381M
| $123K | ﹤0.01% |
+11,646
| New | +$128K |
|
2874
Zura Bio
ZURA
$604M
| $121K | ﹤0.01% |
94,055
-12,571
| -12% | -$19.8K |
|
2875
Inseego
INSG
$72.1M
| $121K | ﹤0.01% |
14,849
-18,102
| -55% | -$198K |
|
Similar funds
John Overdeck's Q1 2025 Portfolio in Review
As of Q1 2025, John Overdeck held 3,617 positions worth $46.8B, up 2% from $45.9B the previous quarter. Its ten largest holdings account for 8.1% of the portfolio.
John Overdeck deployed $2.08B of net new capital in Q1 2025, opening 458 new positions and adding to 1,225 existing holdings. Its largest new stake was Advanced Micro Devices: 2,246,952 shares worth $231M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $255M trimmed.
- John Overdeck's largest Q1 2025 buy was Advanced Micro Devices: 2,246,952 shares worth $231M.
- John Overdeck added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $510M increase.
- John Overdeck's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $255M.
- John Overdeck fully exited Coinbase in Q1 2025, selling an estimated $45M.
- John Overdeck's ten largest holdings make up 8.1% of its $46.8B portfolio in Q1 2025.
- John Overdeck opened 458 new positions and closed 452 in Q1 2025.
- John Overdeck's portfolio value rose 2% quarter-over-quarter to $46.8B.
Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.